Answers are grounded in this paper and cite their sources.
Clinical study reports higher incidence of PD-1 inhibitor-related pneumonitis in NSCLC, RCC, and combination therapy, highlighting the need for vigilance.
The incidence of PD-1 inhibitor-related pneumonitis was higher in NSCLC and RCC and during combination therapy. These findings contribute to enhance awareness among clinicians and support further investigations to meet the clinical needs.
No takes yet. Share an insight, caveat, or question.
Nishino et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: